That is my thinking as well. The Phase 2b trial with over 300...

That is my thinking as well. The Phase 2b trial with over 300 participants (not 30) went very well, and moving to 900 in Phase 3 with a nearly identical protocol is, mathematically speaking, almost a sure thing mathematically speaking to see a reproduction of the Phase 2b results in Phase 3. So, the risk sits outside of mathematical predictions

As many here have mentioned, there are no sure bets in Phase 3 trials, but I am at a loss as to what the high-IQ analysts internally at the big pharma could be imagining. Or perhaps OPT has rejected their multibillion-dollar advances.

Certainly, I'm thinking of big buy if OPT's stock gets into the 40s.

Interesting speculation that a low stock price may force OPT's hand into accepting a bad deal as the possibility of a CR is diminished.